Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

BRADLEY R HOUTS

Allopathic & Osteopathic Physicians Emergency Medicine

NPI
1881688299
CMS profile
1185430
Location
NORTH KANSAS CITY, MO

General Payments · PY2018–2024

$195,811.31

  • Reported across 95 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$57,683.38

26 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $57,683.38 26

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $57,683.38 26

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $10.87 1
PY2019 $15,288.09 9
PY2020 $26,000.04 12
PY2021 $24,712.19 15
PY2022 $31,850.04 14
PY2023 $40,266.70 18
PY2024 $57,683.38 26

Payment records · PY2024 (26)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 01/17/2024 Consulting Fee Undisputed 01/23/2026 1137580113 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,325.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 1137580117 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 02/14/2024 Consulting Fee Undisputed 01/23/2026 1137580120 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,325.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 1137580124 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,325.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 1137580127 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 03/11/2024 Consulting Fee Undisputed 01/23/2026 1137580131 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,325.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137580135 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137580139 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,325.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 1137580142 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 05/10/2024 Consulting Fee Undisputed 01/23/2026 1137580146 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,325.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137580150 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137580153 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,325.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137580157 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137580161 CMS
Takeda Pharmaceuticals U.S.A., Inc. $591.67 07/26/2024 Consulting Fee Undisputed 01/23/2026 1137580165 CMS
Takeda Pharmaceuticals U.S.A., Inc. $591.67 07/26/2024 Consulting Fee Undisputed 01/23/2026 1137580168 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,325.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1137580171 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 08/09/2024 Consulting Fee Undisputed 01/23/2026 1137580175 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,325.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 1137580179 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 09/11/2024 Consulting Fee Undisputed 01/23/2026 1137580182 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,325.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 1137580186 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 10/09/2024 Consulting Fee Undisputed 01/23/2026 1137580190 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 11/13/2024 Consulting Fee Undisputed 01/23/2026 1137580193 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,425.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 1137580197 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,425.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 1137580201 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 12/09/2024 Consulting Fee Undisputed 01/23/2026 1137580204 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.